PPD Stock

PPD P/B

Delisted

The P/B (Price-to-Book Ratio) of PPD (PPD) as of Sep 7, 2026 is -22.26. In the previous year, P/B (Price-to-Book Ratio) was -6.16 — a change of 261.43% (lower).

P/B

-22.26

YoY

261.43%

Last updated:

P/B (Price-to-Book Ratio) of PPD is 2026 -22.26 . P/B (Price-to-Book Ratio) of PPD was 2025 -6.16 . It decreases by 261.43% lower compared to the previous year.

The PPD P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2017
-11.14 USD
Jan 1, 2018
-10.91 USD
Jan 1, 2019
-6.16 USD
Jan 1, 2020
-22.26 USD
The PPD P/B history
YEARP/BYoY
-22.26+261.43%
-6.16-43.58%
-10.91-2.02%
-11.14
Access this data via the Eulerpool API

PPD Stock analysis

What does PPD do? PPD Inc is a global company for medical research and services that was founded in 1985 and is headquartered in Wilmington, North Carolina, USA. The company is known for its ability to conduct clinical trials and develop research programs for the biopharmaceutical and medical industry. PPD is a leading provider of comprehensive, integrated services for phases I-IV of clinical research, from non-interventional studies to contract research for pharmaceutical and biotech clients. PPD's business model is based on three key pillars to provide customers with a broad portfolio of services: the first pillar is comprehensive clinical research required for drug registration with regulatory authorities, the second pillar focuses on providing research-based data and analytical methods to facilitate decision-making and risk assessment in the healthcare sector, and the third pillar encompasses extensive laboratory analyses and diagnostic tests to improve patient health and support research efforts. PPD has multiple divisions focused on specific markets and customers. The Clinical Trials division offers services for drug development up to approval by regulatory authorities, including the setup and monitoring of clinical trials and statistical analysis of test results. The Data Management division provides data capture and management solutions for clinical trials to ensure high data quality and compliance with regulations. The Medical Monitoring division offers medical consultation and monitoring during clinical trials. PPD also has a division for Real World Evidence studies, which collects data from routine clinical practice to assess the safety and efficacy of drugs. PPD has made some important acquisitions in the past to strengthen its presence in the industry. In 2011, PPD was acquired by private equity firms Carlyle Group and Hellman & Friedman, becoming a private company. In 2020, PPD went public. In 2018, PPD acquired Evidera, a company specializing in clinical epidemiology and outcomes research. In 2019, PPD acquired Q-Squared Solutions, expanding its extensive laboratory analysis and diagnostic testing capabilities. PPD's offerings include a wide range of products and services, including unique planning and implementation solutions that enable efficient conduct of clinical trials. These solutions also include electronic data capture and management systems, as well as statistical analysis tools. PPD also offers specialized services, such as training programs for clinical investigators and staff. PPD aims to enable safe, faster, and cost-effective drug development through clinical research. In the future, PPD will continue to expand its business model and services to meet the needs of its customers in the changing industry and support innovative research programs. PPD is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PPD stock

P/B (Price-to-Book Ratio) of PPD is -22.26 in 2026.

P/B (Price-to-Book Ratio) of PPD changed from -6.16 to -22.26, representing a 261.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) PPD since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s PPD with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — PPD

All Key Metrics — PPD